SCHEMBL4049957

SCHEMBL4049957

FC(F)(F)Oc1ccc(-c2nc3ncc(-c4cccc5ccccc45)cc3[nH]2)cc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AURKA O14965 3/20 0.44
SCD O00767 1/20 0.42
TRPV1 Q8NER1 1/20 0.41
BACE1 P56817 1/20 0.40
BRAF P15056 1/20 0.40
IKBKE Q14164 6/20 0.40
TBK1 Q9UHD2 6/20 0.40
AURKB Q96GD4 2/20 0.40
CDK2 P24941 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
PPARG P37231 1/20 0.39
PPARD Q03181 1/20 0.39
PPARA Q07869 1/20 0.39
DHODH Q02127 1/20 0.39
RUNX1 Q01196 1/20 0.39
CBFB Q13951 1/20 0.39
PRMT5 O14744 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4055069 0.87 SCD (0.56) AURKASCDTRPV1BRAFIKBKE
SCHEMBL4055464 0.86 AURKA (0.60) AURKAIKBKETBK1AURKBCDK2
SCHEMBL4059384 0.84 AURKA (0.55) AURKATRPV1IKBKETBK1AURKB
SCHEMBL4057426 0.84 AURKA (0.48) AURKASCD
SCHEMBL13607913 0.83 TRPV1 (0.41) TRPV1BACE1CDK2CYP2C9CYP2C19
SCHEMBL4053038 0.80 AURKA (0.49) AURKATRPV1IKBKETBK1AURKB
SCHEMBL4061866 0.79 AURKA (0.57) AURKAIKBKETBK1AURKBCDK2
SCHEMBL4053861 0.78 AURKA (0.59) AURKAIKBKETBK1AURKBCDK2
SCHEMBL4053465 0.77 IKBKE (0.49) AURKATRPV1BRAFIKBKETBK1
SCHEMBL4057667 0.77 AURKA (0.60) AURKATRPV1BRAFPRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B AURKA 247/4885SCD 4559/4885TRPV1 2690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.